<DOC>
	<DOCNO>NCT01482845</DOCNO>
	<brief_summary>This study investigate safety , tolerability pharmacokinetics ABT-126 20 male female subject , 55 90 year age mild moderate Alzheimer 's disease stable dose acetylcholinesterase inhibitor .</brief_summary>
	<brief_title>A Phase 1 Study Safety , Tolerability Pharmacokinetics ABT-126 Subjects With Alzheimer 's Disease</brief_title>
	<detailed_description>This double-blind , placebo-controlled , randomize , multiple-dose , parallel group , multicenter study . Up 20 male female subject mild moderate Alzheimer 's disease ( AD ) take stable dos acetylcholinesterase inhibitor enrol study . The study conduct four site . Within 28 day prior study drug administration , subject screen base National Institute Neurological Communicative Disorders Stroke/Alzheimer 's Disease Related Disorders Association ( NINCDS/ADRDA ) criteria probable AD , Mini-Mental State Examination ( MMSE ) Modified Hachinski Ischemic Scale ( MHIS ) score , medical history , physical examination , neurological examination , vital sign , ECG , laboratory test response Columbia-Suicide Severity Rating Scale ( C-SSRS ) . Subjects divide two group 10 subject . In group , 8 subject receive ABT-126 two subject receive match placebo . Group 1 administer Dose 1 ABT-126 placebo . Group 2 administer Dose 2 ABT-126 placebo . All dos administer daily morning 10 day .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cholinesterase Inhibitors</mesh_term>
	<criteria>Inclusion Criteria 1 . Male female age 55 90 year , inclusive . 2 . The subject meet National Institute Neurological Communicative Disorders Stroke/Alzheimer 's Disease Related Disorders Association ( NINCDS/ADRDA ) criteria probable Alzheimer 's Disease ( AD ) . 3 . The subject MiniMental State Examination ( MMSE ) total score 16 26 , inclusive , Screening Visit . 4 . The subject Modified Hachinski Ischemic Scale ( MHIS ) score â‰¤ 4 Screening Visit . 5 . The subject must stable dose donepezil rivastigmine least 1 month prior study drug administration . 6 . The subject computerized tomography magnetic resonance imaging scan , interpreted radiologist neurologist , within 36 month prior randomization subject meet NINCDS/ADRDA diagnostic criterion probable AD . The scan must show evidence alternative etiology dementia . Exclusion Criteria 1 . Receipt investigational product within 6 week prior study drug administration . 2 . History significant sensitivity allergy drug . 3 . History significant neurological disease AD . 4 . Significant current suicidal ideation within 1 month prior study drug administration evidence answer `` yes '' question 4 5 suicidal ideation portion ColumbiaSuicide Severity Rating Scale ( CSSRS ) complete Screening history suicide attempt .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>